An Exploratory Clinical Study Evaluating the Efficacy and Safety of Tunlametinib Combined With Fruquintinib in the Third-line Treatment of Advanced Colorectal Cancer Patients With RAS Mutations.

NCT06985316 · clinicaltrials.gov ↗
NA
Phase
NOT_YET_RECRUITING
Status
34
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Liu Huang